CA2879478C - Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror.gamma. - Google Patents

Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror.gamma. Download PDF

Info

Publication number
CA2879478C
CA2879478C CA2879478A CA2879478A CA2879478C CA 2879478 C CA2879478 C CA 2879478C CA 2879478 A CA2879478 A CA 2879478A CA 2879478 A CA2879478 A CA 2879478A CA 2879478 C CA2879478 C CA 2879478C
Authority
CA
Canada
Prior art keywords
alkyl
alkylene
cycloalkyl
compound
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2879478A
Other languages
English (en)
French (fr)
Other versions
CA2879478A1 (en
Inventor
Christian Gege
Olaf Kinzel
Christoph Steeneck
Gerald Kleymann
Thomas Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenex Pharmaceuticals AG
Original Assignee
Phenex Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46754230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2879478(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Phenex Pharmaceuticals AG filed Critical Phenex Pharmaceuticals AG
Publication of CA2879478A1 publication Critical patent/CA2879478A1/en
Application granted granted Critical
Publication of CA2879478C publication Critical patent/CA2879478C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2879478A 2012-08-09 2013-05-29 Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror.gamma. Expired - Fee Related CA2879478C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261681296P 2012-08-09 2012-08-09
EP12005789.8 2012-08-09
US61/681,296 2012-08-09
EP12005789 2012-08-09
PCT/EP2013/001594 WO2014023367A1 (en) 2012-08-09 2013-05-29 Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma

Publications (2)

Publication Number Publication Date
CA2879478A1 CA2879478A1 (en) 2014-02-13
CA2879478C true CA2879478C (en) 2017-08-22

Family

ID=46754230

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2879478A Expired - Fee Related CA2879478C (en) 2012-08-09 2013-05-29 Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror.gamma.

Country Status (27)

Country Link
US (1) US9458104B2 (OSRAM)
EP (2) EP3118189A1 (OSRAM)
JP (1) JP6097829B2 (OSRAM)
KR (1) KR101732973B1 (OSRAM)
CN (1) CN104603105B (OSRAM)
AR (1) AR091193A1 (OSRAM)
AU (1) AU2013301914B2 (OSRAM)
BR (1) BR112015002738A2 (OSRAM)
CA (1) CA2879478C (OSRAM)
CL (1) CL2015000300A1 (OSRAM)
CO (1) CO7310529A2 (OSRAM)
EA (1) EA027953B9 (OSRAM)
GT (1) GT201500024A (OSRAM)
IL (1) IL236695A (OSRAM)
IN (1) IN2015DN01815A (OSRAM)
JO (1) JO3215B1 (OSRAM)
MX (1) MX364453B (OSRAM)
NO (1) NO344067B1 (OSRAM)
NZ (1) NZ704512A (OSRAM)
PE (1) PE20150463A1 (OSRAM)
PH (1) PH12015500142B1 (OSRAM)
SG (1) SG11201500955RA (OSRAM)
TW (2) TW201527278A (OSRAM)
UA (1) UA115145C2 (OSRAM)
UY (1) UY34833A (OSRAM)
WO (1) WO2014023367A1 (OSRAM)
ZA (1) ZA201500534B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659019B (zh) * 2014-02-28 2019-05-11 日商帝人製藥股份有限公司 吡唑醯胺衍生物
AU2015267911B2 (en) * 2014-05-28 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Novel compounds
BR112016028119A2 (pt) 2014-06-06 2017-08-22 Res Triangle Inst Agonistas receptores de apelina (apj) e usos dos mesmos
US9861618B2 (en) 2014-10-30 2018-01-09 Janssen Pharmaceutica Nv Thiazoles as modulators of RORγt
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
EP3101006A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN108602806B (zh) 2015-12-09 2022-07-12 研究三角协会 改进的爱帕琳肽受体(apj)激动剂及其用途
US20200288710A1 (en) 2016-03-15 2020-09-17 Bayer Cropscience Aktiengesellschaft Substituted sulphonamides for controlling animal pests
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
AU2017343638B2 (en) * 2016-10-12 2021-12-09 Research Triangle Institute Heterocyclic apelin receptor (APJ) agonists and uses thereof
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020059651A (ja) * 2016-12-26 2020-04-16 科研製薬株式会社 ピラゾール誘導体及びそれを含有する医薬
JP2020142989A (ja) * 2017-06-21 2020-09-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
US10654828B2 (en) 2017-07-28 2020-05-19 Novartis Ag Indole derivatives and uses thereof
CN109485595B (zh) * 2017-09-12 2022-05-27 江苏恒瑞医药股份有限公司 亲水性基团取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
US10633350B2 (en) 2017-09-13 2020-04-28 Novartis Ag Diphenyl derivatives and uses thereof
AR114270A1 (es) 2018-02-28 2020-08-12 Japan Tobacco Inc Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
EP3807261B1 (en) * 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl pyrazoles as modulators of roryt
CN112292183A (zh) * 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
CA3103770A1 (en) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
CN111484505B (zh) * 2019-01-28 2022-11-15 正大天晴药业集团股份有限公司 一种双环RORγ抑制剂的盐酸盐结晶型
CN118496198A (zh) 2019-07-23 2024-08-16 拜耳公司 作为农药的新的杂芳基-三唑化合物
JP2023501978A (ja) 2019-11-07 2023-01-20 バイエル・アクチエンゲゼルシヤフト 動物害虫駆除用の置換スルホニルアミド
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
HRP950330A2 (en) 1994-07-05 1997-10-31 Ciba Geigy Ag New herbicides
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US6413997B1 (en) 1998-10-23 2002-07-02 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted heterocyclyl)-1,2,4-triazole compounds
MXPA02005100A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de pirazol antagonistas de receptor de canabinoide.
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
WO2001064669A1 (en) 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
EP1421077A4 (en) 2001-08-31 2004-11-17 Univ Connecticut NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS
WO2003037335A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
CA2493156A1 (en) 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
CA2495216A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
EP1433788A1 (en) 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
CN101012193A (zh) * 2003-01-02 2007-08-08 霍夫曼-拉罗奇有限公司 新cb 1受体反激动剂
WO2004092140A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
JPWO2004094407A1 (ja) 2003-04-21 2006-07-13 第一製薬株式会社 ５員複素環誘導体
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
ES2324720T3 (es) 2004-05-10 2009-08-13 F. Hoffmann-La Roche Ag Pirrol o imidazol amidas para tratar la obesidad.
ZA200700751B (en) * 2004-06-30 2008-08-27 Vertex Pharma Azalndoles useful as inhibitors of protein kinases
WO2006004984A1 (en) 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
EA011725B1 (ru) 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
EP1881991A1 (en) 2005-05-19 2008-01-30 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2006133926A1 (en) * 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
NZ564916A (en) 2005-06-27 2011-03-31 Exelixis Inc Imidazole based LXR modulators
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
WO2007024744A2 (en) 2005-08-21 2007-03-01 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
CA2660261A1 (en) 2006-08-09 2008-02-14 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
BRPI0720732A2 (pt) 2006-12-18 2014-04-08 7Tm Pharma As Moduladores de receptor cb1
EP1946778A1 (en) 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Active substance combination for the treatment of diabetes
EP2114916A2 (en) 2007-02-02 2009-11-11 NeuroSearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
KR100917037B1 (ko) 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
EP2238127B1 (en) * 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009097486A1 (en) 2008-01-31 2009-08-06 The Scripps Research Institute OXAZOLE-PYRROLE-PIPERAZINE α-HELIX MIMETIC
CN101544631B (zh) 2008-03-26 2012-05-23 中国科学院上海药物研究所 吡唑类5-脂氧酶小分子抑制剂及其制备方法、药物组合物和应用
WO2010038948A2 (en) 2008-10-02 2010-04-08 Green Cross Corporation Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
WO2010048559A2 (en) 2008-10-24 2010-04-29 Calcimedica Inc. Phenylpyrazole inhibitors of store operated calcium release
EP2181710A1 (en) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8653112B2 (en) 2009-10-07 2014-02-18 Karo Bio Ab Substituted pyrazoles as estrogen receptor ligands
UY33200A (es) 2010-01-26 2011-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
EP3002008B8 (en) 2010-03-11 2018-10-24 New York University Amido compounds as roryt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
WO2012064631A1 (en) 2010-11-10 2012-05-18 Boehringer Ingelheim International Gmbh Pyridyl ureas as mineralocorticoid receptor antagonists
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
WO2012100734A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
DK2668183T3 (da) 2011-01-28 2018-01-29 4Sc Discovery Gmbh Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammation
CA2825684C (en) 2011-01-28 2021-11-23 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
CA2736441A1 (en) 2011-04-06 2012-10-06 The Regents Of The University Of California Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
JP5976778B2 (ja) 2011-04-11 2016-08-24 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
EP2511263A1 (en) * 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
JP5902029B2 (ja) 2011-04-28 2016-04-13 日本たばこ産業株式会社 アミド化合物およびその医薬用途
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2013000871A1 (en) 2011-06-27 2013-01-03 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
EP2723889B1 (en) 2011-06-27 2019-11-06 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
CN105646362B (zh) 2011-07-26 2019-07-05 赛诺菲 3-杂芳酰基氨基-丙酸衍生物及其作为药物的用途
WO2013019682A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013019621A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2747560A4 (en) 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
EP2738170B1 (en) 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20140155381A1 (en) 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
RU2014113926A (ru) 2011-09-09 2015-10-20 Нью Йорк Юниверсити АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ
JP2014526494A (ja) 2011-09-19 2014-10-06 イーティーエイチ・チューリッヒ ＲＯＲγ修飾剤
US9120776B2 (en) 2011-09-22 2015-09-01 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
US9815851B2 (en) * 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
JP6225178B2 (ja) 2012-05-31 2017-11-01 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体

Also Published As

Publication number Publication date
US9458104B2 (en) 2016-10-04
EA201590092A1 (ru) 2015-08-31
CL2015000300A1 (es) 2015-07-10
PH12015500142A1 (en) 2015-03-16
CO7310529A2 (es) 2015-06-30
AR091193A1 (es) 2015-01-21
ZA201500534B (en) 2016-10-26
MX2015001728A (es) 2015-04-14
JP2015524449A (ja) 2015-08-24
NO344067B1 (en) 2019-08-26
IL236695A (en) 2017-07-31
JO3215B1 (ar) 2018-03-08
EP2882710A1 (en) 2015-06-17
AU2013301914A1 (en) 2015-02-05
UA115145C2 (uk) 2017-09-25
PH12015500142B1 (en) 2015-03-16
CN104603105A (zh) 2015-05-06
KR20150040354A (ko) 2015-04-14
PE20150463A1 (es) 2015-04-23
IL236695A0 (en) 2015-02-26
EP2882710B1 (en) 2016-09-07
IN2015DN01815A (OSRAM) 2015-05-29
JP6097829B2 (ja) 2017-03-15
NO20150112A1 (en) 2015-01-23
TWI488839B (zh) 2015-06-21
US20150344423A1 (en) 2015-12-03
GT201500024A (es) 2017-08-24
MX364453B (es) 2019-04-26
HK1211584A1 (en) 2016-05-27
CA2879478A1 (en) 2014-02-13
AU2013301914B2 (en) 2016-08-18
AU2013301914A8 (en) 2015-02-12
TW201527278A (zh) 2015-07-16
CN104603105B (zh) 2017-09-08
WO2014023367A1 (en) 2014-02-13
TW201406723A (zh) 2014-02-16
EP3118189A1 (en) 2017-01-18
NZ704512A (en) 2016-09-30
EA027953B1 (ru) 2017-09-29
EA027953B9 (ru) 2018-01-31
UY34833A (es) 2013-12-31
SG11201500955RA (en) 2015-03-30
BR112015002738A2 (pt) 2018-05-22
KR101732973B1 (ko) 2017-05-08

Similar Documents

Publication Publication Date Title
CA2879478C (en) Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror.gamma.
CA2873877C (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
CA2856946C (en) Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases
AU2010304740B2 (en) Pyrazole derivatives as modulators of calcium release -activated calcium channel
EP2511263A1 (en) Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
UA113625C2 (xx) Похідні піразолідин-3-ону
CA3241593A1 (en) Bifunctional sulphonamide compounds
HK1211584B (en) Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma
JP2022521895A (ja) ファルネソイドｘ受容体モジュレータとしての置換二環式化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150119

MKLA Lapsed

Effective date: 20210531